Shionogi's redasemtide fails Phase 2 stroke trial; Bayer's Hyrnuo expands FDA label; Tevard, Disc, InduPro, EMD Serono/PostEra & Frazier news.
Plus news about Tevard Biosciences, Disc Medicine, InduPro, EMD Serono and Frazier Life Sciences.
Shionogi fails mid-stage stroke trial: The company’s experimental drug redasemtide
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Arrowhead's Redemplo shows a stronger safety edge than Ionis' Tryngolza in new Phase 3 sHTG data, sharpening a fast-approaching…
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.
Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push…
Bayer still plans to launch stroke drug asundexian in every country possible including Germany, despite a pricing-bill fight;…
In an accelerated decisio | Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
